Lewy body disease (LBD) is the second most common

Size: px
Start display at page:

Download "Lewy body disease (LBD) is the second most common"

Transcription

1 REGULAR ARTICLES Lewy Body Disease: Can We Diagnose It? Michelle Papka, Ph.D. Ana Rubio, M.D., Ph.D. Randolph B. Schiffer, M.D. Christopher Cox, Ph.D. The authors assessed the accuracy of published clinical criteria and their own modifications of those criteria in diagnosing Lewy body disease (LBD). Clinical diagnoses were made by two clinicians, blinded to neuropathologic diagnoses, using the Rochester Alzheimer s Disease Center database and traditional medical records. Neuropathologic diagnoses were made according to published guidelines. Results from 21 Alzheimer s disease and 18 LBD patients indicated that no set of clinical criteria was accurate in diagnosing LBD. The only significant predictor of LBD in this population was depression, which was more common in LBD than in Alzheimer s disease. The authors conclude that clinical identification of LBD is an important but unresolved neurological problem. (The Journal of Neuropsychiatry and Clinical Neurosciences 1998; 10: ) Lewy body disease (LBD) is the second most common pathologic correlate of dementia in the elderly, following Alzheimer s disease (AD). 1 Neuropathologic findings in LBD patients usually include those of both typical AD and Parkinson s disease (PD). More rarely, LBD patients may present only with Lewy bodies in the brainstem and cortex, without any Alzheimer s pathology. These patients have been referred to as pure LBD patients. In the past, there has been no concordance among neuropathologists on criteria for diagnosing LBD. Relatively recently, consensus guidelines for the neuropathologic diagnosis of LBD have been proposed, 2 although these have yet to be validated across patient populations. It is the co-occurrence of these two different pathologies that complicates both neuropathologic and clinical diagnosis of LBD. The most commonly reported clinical symptoms associated with LBD are progressive dementia, extrapyramidal signs, visual hallucinations and delusions, and cognitive fluctuations. 3 Other associated features include sensitivity to antipsychotic drugs, orthostatic hypotension, transient clouding of consciousness, syncope, and falling. The similarity of neuropathologic and clinical symptoms of LBD to those of AD and PD has led to Received December 17, 1997; revised March 3, 1998; accepted March 25, From the Department of Neurology and Alzheimer s Disease Research Center and the Departments of Neurology, Pathology, Laboratory Medicine, Psychiatry, Environmental Medicine, and Biostatistics, University of Rochester Medical Center, Rochester, New York. Address correspondence to Dr. Papka, Department of Neurology, Box 673, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642; mpapka@mail.neurology.rochester.edu Copyright 1998 American Psychiatric Press, Inc. JOURNAL OF NEUROPSYCHIATRY 405

2 DIAGNOSIS OF LEWY BODY DISEASE an overlapping range of terms being used to describe these patients. Among these are the LB variant of AD, senile dementia of the LB type, diffuse LB disease, and PD in AD. Several sets of criteria for the clinical diagnosis of LBD have been proposed. Among the most influential were the criteria set forth by McKeith et al. in These criteria, shown in Table 1, are based on a retrospective study of 21 autopsy-determined LBD cases. Applied to one sample of LBD and AD patients, 4 these criteria, on retrospective review, identified 71% of LBD cases on initial presentation and 86% between presentation and death. Cross-validation of these criteria by the same researchers in a sample of LBD, AD, and multi-infarct dementia (MID) patients yielded a sensitivity rate of 74% and a specificity of 95%. 5 In this latter study, it was reported that less experienced clinicians were more likely to misdiagnose LBD as AD or MID because of a failure to recognize cognitive fluctuations unique to LBD. In our attempt to use the McKeith et al criteria with patients evaluated in the University of Rochester Alzheimer s Disease Center (ADRC), we also found these cognitive fluctuations difficult to detect in clinical practice. Furthermore, we hypothesized that all patients with LBD would have at least some extrapyramidal signs, since these patients evidence subcortical LBs at autopsy. The importance of extrapyramidal signs in making a clinical diagnosis of LBD has been supported by Mega et al., 6 who found that cogwheeling, rigidity, and bradykinesia were 3 of 6 symptoms that helped to distinguish LBD from AD patients. Hence, we adopted a modified version of the McKeith et al criteria, TABLE 1. McKeith et al. 4 operational criteria for Lewy body disease A. Fluctuating cognitive impairment affecting both memory and higher cortical functions (such as language, visuospatial ability, praxis, or reasoning skills); the fluctuation is marked by the occurrence of both episodic confusion and lucid intervals, as in delirium, and is evident either on repeated tests of cognitive function or by variable performance in daily living skills B. At least one of the following: 1. Visual and/or auditory hallucinations usually accompanied by secondary paranoid delusions 2. Mild spontaneous extrapyramidal features or neuroleptic sensitivity syndrome (i.e., exaggerated adverse responses to standard doses of neuroleptic medication) 3. Repeated unexplained falls and/or transient clouding or loss of consciousness C. Despite the fluctuating pattern, other clinical features persist over a long period of time (weeks or months), unlike delirium, which rarely persists as long D. Exclusion of any underlying physical illness adequate to account for the fluctuating cognitive state by appropriate examination and investigation E. Exclusion of past history of confirmed stroke and/or evidence of cerebral ischemic damage on structural brain imaging shown in Table 2. This modification required the presence of at least one extrapyramidal sign sometime during the early to moderate course of the disease. We also considered that depression, reported to be more prevalent in LBD than AD patients in at least one study, 7 might distinguish LBD from AD patients in this sample. Therefore, we recorded this variable separately. The most recent set of operational criteria for LBD, 2 largely based on the McKeith et al criteria, was developed during the 1996 proceedings of the First International Workshop of the Consortium on Dementia with Lewy Bodies. The report from this consortium acknowledges the difficulty of assessing fluctuating cognition; the consensus criteria for the clinical diagnosis of LBD (termed dementia with Lewy bodies) include this as a core, but not essential, feature of the disease. 2 The consensus criteria for making a diagnosis for probable and possible LBD are outlined in Table 3. These consensus criteria were applied retrospectively TABLE 2. TABLE 3. Proposed criteria for Lewy body disease: modifications of McKeith et al. 4 A. Presence of a cortical dementia B. Presence of at least one extrapyramidal feature C. At least one of the following: 1. Hallucinations or delusions 2. Adverse reactions to antipsychotic or antidepressant drugs 3. Repeated unexplained falls 4. Fluctuating cognitive impairment D. Gradual progression of symptoms E. Exclusion of other physical illnesses that may account for the symptoms F. Exclusion of past history of confirmed stroke and/or evidence of cerebral ischemic damage on structural brain imaging Consensus criteria for the clinical diagnosis of dementia with Lewy bodies 2 A. Progressive cognitive decline of sufficient magnitude to interfere with normal social or occupational function B. Two of the following are essential for a diagnosis of probable LBD; one for a diagnosis of possible LBD: 1. Fluctuating cognition 2. Recurrent visual hallucinations 3. Spontaneous parkinsonism C. Features supportive of the diagnosis: 1. Repeated falls 2. Syncope 3. Transient losses of consciousness 4. Neuroleptic sensitivity 5. Systematized delusions 6. Hallucinations in other modalities D. Diagnosis less likely in the presence of: 1. Stroke confirmed by clinical focal findings and/or brain imaging 2. Evidence of other physical illness or brain disorder that may account for the clinical findings 406 VOLUME 10 NUMBER 4 FALL 1998

3 PAPKA et al. by Mega et al. 6 to 24 patients who had received premortem diagnoses of AD, PD, or progressive supranuclear palsy (PSP). The sensitivity and specificity of these criteria were 75% and 79%, respectively, for cases found to have many LBs at autopsy (4 or more LBs in at least 3 cortical 250 fields). Equal sensitivity (75%) and 100% specificity were attained in this sample when the presence of hallucinations, cogwheeling, rigidity, bradykinesia, neuroleptic sensitivity, and cognitive fluctuations were used as clinical criteria for LBD. The purpose of the present study was to assess the accuracy of the McKeith et al criteria, 4 the consensus criteria, 2 and our own proposed criteria in detecting autopsy-confirmed LB pathology. Two clinicians (M.P., R.S.), blinded to autopsy diagnosis, determined by agreement whether each of 46 patients met specified LBD criteria using the Rochester ADRC database and traditional medical charts. Neuropathologic diagnosis was made by one investigator (A.R.) using published guidelines. 2,8 The goal was to determine the utility of consensus criteria and the presence of extrapyramidal signs in accurate clinical diagnosis of LBD. METHODS Subjects All patients listed in the Rochester ADRC Neuropathology Database with a neuropathologic diagnosis of LBD (not excluding concomitant AD pathology) were selected as subjects (n 23). For each LBD subject, a patient with the neuropathologic diagnosis of AD was selected from the same database on the basis of temporal proximity to the time of death of selected LBD cases. For both subject groups, only patients without other significant neuropathology (e.g., strokes) were included. In total, the initial sample population consisted of 46 subjects, all of whom had given written consent to participation and enrollment in the Rochester ADRC Neuropathology Study. Neuropathologic Procedures and Diagnosis The brain was removed and dissected fresh according to the current protocol of the Rochester ADRC. Among the 24 Formalin-fixed paraffin-embedded sections obtained by this protocol, 10 were examined specifically for this study. Sections included all neocortical lobes, cingulum, anterior and posterior hippocampus with parahippocampal cortex, basal ganglia with insula, and midbrain with substantia nigra. In addition to hematoxylin and eosin (H&E) stains, silver (Yamamoto-Hirano modified Bielchowsky) stain, amyloid (congo red and b- amyloid immunostain), ubiquitin and paired helical filament immunostaining were applied following the standardized biotin streptavidin (ABC) method. The presence, severity, and topographic extent of AD pathology in both patient groups were determined by using simplified Braak and Braak (B&B) staging criteria. 8 Following the National Institutes of Health recommendation for the diagnosis of AD, 9 we categorized the dementia as mild when B&B stages were 1 or 2, moderate for B&B stages 3 and 4, and severe for B&B stages 5 and 6. All cases were evaluated for the presence or absence of LBs, following the consensus guideline pathologic criteria. 2 Slight modifications of this protocol were made (study of posterior cingulum and superior temporal gyrus instead of anterior cingulum and middle temporal gyrus) on the basis of tissue availability. The presence of LBs was a necessary condition for the LBD diagnosis. The specific algorithm used for evaluating and counting LBs is shown in Figure 1. These evaluations were conducted on preserved tissue of patients whose autopsies predated the published consensus guidelines for neuropathologic diagnosis of LBD. Clinical Diagnosis Two clinicians, one a neuropsychologist (M.P.) and one a neuropsychiatrist (R.S.), both blinded to neuropathologic diagnosis, reviewed the medical history of each subject. Histories were comprised from standardized data forms completed for all subjects enrolled in the Rochester ADRC study and from traditional medical charts maintained by the University of Rochester Medical Center. The ADRC data forms contain variables summarizing demographic and medical information for each patient. Included in these forms are measures of psychiatric features such as hallucinations, delusions, and depression, as well as extrapyramidal features including rigidity, bradykinesia, tremor, and impaired gait. For these items, the presence or absence of a particular symptom is noted along with any relevant descriptors. The forms are completed annually by registered, Master s-level nurses with specialized training and experience in geriatrics. Completion of these forms is based on information collected by ADRC nurses, including patient evaluation, interviews with the patient s family members, and past medical records. Assessments are made according to a standardized protocol developed by geriatric neurologists, neuropsychologists, and neurologists in the ADRC. To help ascertain accuracy of clinical assessments, all completed forms are reviewed by the Research Nurse Coordinator and then by the Data Coordinator to ensure completeness and consistency. Explicit documentation in clinical notes or endorsement on the structured database forms was necessary JOURNAL OF NEUROPSYCHIATRY 407

4 DIAGNOSIS OF LEWY BODY DISEASE for a symptom to be considered present. Although not a variable on any set of criteria, the presence or absence of depressive symptoms sufficient to warrant chartbased diagnosis or to justify the prescription of antidepressant medication was also recorded. After reviewing the medical history of each subject, it was determined by agreement between both clinical investigators (M.P., R.S.) whether or not each subject met each set of criteria (see Tables 1 3). Statistical Methods Chi-square and Fisher s exact test were used to compare groups of patients. The predictive power of various clinical variables was assessed by multiple logistic regression with neuropathologic diagnosis (presence vs. absence of LBs) as the dependent variable. In addition to these confirmatory analyses, an exploratory analysis using forward stepwise selection of variables was performed. This stepwise procedure was used because the small sample size precluded an analysis considering all variables simultaneously. The purpose of this exploratory analysis was to identify additional predictors of LBD that could be prospectively test-validated by using different and larger groups of patients. RESULTS Seven subjects were excluded from the study: 6 had insufficient medical documentation for clinical ratings and 1 had cerebral palsy. Results are based on the data from 39 patients, 21 of whom had autopsy-confirmed AD and 18 of whom had LB pathology with concomitant AD changes. Neuropathologic classification, stage, and severity for each group are outlined in Table 4. Demographics for both groups are shown in Table 5. There were no significant differences between LBD and pure AD groups on the basis of gender, age at disease onset, age at death, or disease duration. However, 5 of the 21 AD patients (23.8%) had an onset age of younger than 60 years, compared with only 1 of 18 LBD patients (5.6%). FIGURE 1. Algorithm for classification and staging of Lewy body disease (LBD). *Locations include substantia nigra, locus ceruleus, and basal forebrain. **Areas are: parahippocampal gyrus at the level of red nucleus; anterior cingulum (immediately anterior to central sulcus); middle frontal; middle temporal; and inferior parietal cortices. The areas to be quantified include the whole thickness of the gyrus for transentorrhinal and cingular locations and half of the gyrus (from tip of the gyrus to depth of the sulcus in neocortical locations). Identification of LBs is made with H&E stained slides with the aid of ubiquitin immunostains. Counts are not conducted directly on anti-ubiquitin immunostains to avoid the overestimation produced by the inclusion of globose tangles in the counts. ***Individual scores for each of the five areas are obtained by registering 0 when no LBs are found, 1 when the LB count ranges from one to five and 2 when there are more than five LBs per area. Individual scores are added to obtain total score. 408 VOLUME 10 NUMBER 4 FALL 1998

5 PAPKA et al. TABLE 4. Sample distribution Alzheimer s Pathology Severity Lewy Body Pathology Neuropathologic Diagnosis Total Moderate Severe Moderate Severe Pure Alzheimer s disease Concomitant Alzheimer s/lewy body pathology Classification of Lewy body pathology Subcortical Limbic Diffuse Only 1 subject had LBD listed in our ADRC database as the clinical diagnosis given by a physician who evaluated the patient during life. In this case, LBD was chosen as the secondary diagnosis. This patient met proposed and consensus criteria for LBD, and the diagnosis was confirmed by autopsy. Because the clinical diagnosis of LBD has been recognized only recently, and was added to our database as a diagnostic category early in 1995, the lack of prospective LBD diagnoses is expected. The addition of the LBD diagnostic category actually postdates the time of autopsy for many cases. None of the three sets of clinical criteria was accurate in detecting LB pathology. The sensitivity and specificity rates of each set of clinical criteria to LB pathology are summarized in Table 6. As shown, the McKeith et al. TABLE 5. Variable TABLE 6. Patient Group Subject demographics Alzheimer s Disease (AD) (n 21) Percentage of subjects correctly classified by using each set of Lewy body disease criteria (sensitivity/ specificity) McKeith et al. 4 (Table 1) Group Criteria Proposed (Table 2) Lewy Body Disease Concomitant AD (n 18) Gender, females/males 12/9 11/7 Onset age, years Mean SD Range Death age, years Mean SD Range Disease duration, years Mean SD Range Consensus 2 (Table 3) Lewy body disease (sensitivity) Alzheimer s disease (specificity) criteria yielded a sensitivity rate of 17% (3/18) and a specificity of 95% (20/21). The high specificity of these criteria is directly related to the high (83%) false negative rate. Fifteen of 18 patients who actually had LB pathology at autopsy did not meet these criteria because there was no evidence of cognitive fluctuations. In fact, only 4 of the 39 patients studied (10.3%) had any evidence of cognitive fluctuations in their medical histories. Three had autopsy-confirmed LBD, and 1 had AD. Because such a small number of subjects met this criterion, which is essential for the diagnosis of LBD in this set, we excluded this set of criteria from the rest of the analyses. Our requirement of at least one extrapyramidal sign for the diagnosis of LBD did not result in more accurate detection of LB pathology. Instead, our proposed set of criteria fell somewhere between the McKeith et al and consensus criteria in terms of accuracy, with a sensitivity of 39% and a specificity of 33%. Additional analyses failed to reveal differences between the consideration of early- and late-occurring parkinsonism in the LBD diagnosis. (In those analyses, late-occurring parkinsonism was defined as having presented within the last year of life.) The consensus criteria yielded a high sensitivity (89%) but low specificity (29%) because many AD patients also met these criteria. Therefore, we assessed whether the more conservative diagnosis of probable LBD (recommended for research purposes) is more accurate than the more lenient diagnosis of possible LBD (recommended for use in clinical practice). Of the 39 subjects studied, 31 (79%) met consensus criteria for possible LBD and 14 (36%) met criteria for probable LBD (in addition to meeting criteria for possible LBD). Among the former group, only 52% (16/31) actually had LB pathology at autopsy, and of the 14 patients who met criteria for probable LBD, only 43% (6/14) had confirmed LBD. Hence, the more conservative diagnosis of probable LBD was not more accurate than a diagnosis of possible LBD in this sample. These results are shown in Figure 2. Further investigation led to the finding that patients who accurately met clinical criteria for possible LBD but not probable LBD tended to have LB pathology JOURNAL OF NEUROPSYCHIATRY 409

6 DIAGNOSIS OF LEWY BODY DISEASE ranging from subcortical (2/10) to limbic (3/10) to neocortical (5/10), whereas patients who correctly met the diagnosis of probable LBD tended to have the most severe form of LBD, present throughout the neocortex. Of the 6 patients who accurately met the diagnosis of probable LBD, 5 (83%) had the neocortical type and 1 (17%) had the limbic type. Including all patients who accurately met clinical criteria for possible LBD, 2/16 (13%) had brainstem type, 4/16 (25%) had limbic type, and 10/16 (63%) had neocortical type. Since all patients with LB pathology had concomitant AD, the question arose as to whether the severity of concomitant AD affected the accuracy of the clinical diagnosis of LBD. Sixty-seven percent (12/18) of LBD cases had severe versus moderate concomitant AD, compared with 86% (18/21) of pure AD cases. We compared separately the sensitivity of the consensus criteria and the proposed criteria in distinguishing patients with LB pathology from those with pure AD as a function of moderate or severe AD pathology. Although the results of this comparison were not statistically significant, accuracy of LBD diagnosis did seem to improve when concomitant AD pathology was less severe. Using our proposed criteria, there was an 18% increase in sensitivity in detecting LBD when concomitant AD changes were moderate rather than severe. Using consensus criteria, there was a 17% increase in sensitivity and a 6% increase in specificity to LBD when concomitant or pure AD was moderate rather than severe. Exploratory logistic regression analyses considering all predictors yielded a model with three variables as predictive of LBD: falls, delusions, and depression. However, of these three variables only depression appeared in the expected direction (i.e., more prevalent in LBD than AD); P , unadjusted for variable selection. As shown in Figure 3, depression was present in 39% of LBD patients compared with 14% of AD patients, yielding an odds ratio of 16.0 with a 95% confidence interval (1.16, 185.2). DISCUSSION Overall, the results of this study fail to confirm sufficient accuracy of any set of clinical criteria tested for predicting LB pathology when it presents with concomitant AD changes. These results generally conflict with those of McKeith and colleagues, who report relative success in distinguishing LBD from AD patients. 2,4,5 Consistent with most other studies, all of the LBD cases in this sample had concomitant AD changes. The accuracy of these clinical criteria in detecting LB pathology in pure LBD cases cannot be determined from this study and, to our knowledge, has not been addressed in any published study. Contrary to our expectations, the presence of extrapyramidal signs did not facilitate more accurate diagnosis of LBD in this sample. This finding differs from that of Mega et al., 6 who reported improved accuracy in the clinical diagnosis of LBD when extrapyramidal signs were a presenting symptom. That extrapyramidal signs did not occur more frequently in our LBD group com- FIGURE 3. Percentage of subjects with Lewy body disease (LBD; 7/18) and Alzheimer s disease (AD; 3/21) who had documented evidence of depression; P FIGURE 2. Percentage of subjects with autopsy-confirmed Lewy body disease (LBD; empty bars) and autopsyconfirmed pure Alzheimer s disease (AD; filled bars) who met clinical consensus criteria for possible LBD (n 31) and probable LBD (n 14). Percentage LBD Consensus Diagnosis 410 VOLUME 10 NUMBER 4 FALL 1998

7 PAPKA et al. pared with our AD group may be explained in several ways. In PD, extrapyramidal symptoms do not usually occur until nearly 80% of substantia nigra neurons are affected. Therefore, brainstem pathology of LBD patients may not always reach a severe enough level to result in clinical signs of parkinsonism. In addition, the substantia nigra of AD patients is grossly affected by neurofibrillary tangles late in the neurodegenerative process, 10 which likely results in clinical parkinsonism. Consensus guidelines 2 identified a majority of autopsy-confirmed LBD patients in this sample, but they also yielded a high false positive rate, indicating that these criteria are not specific to LBD. The more conservative consensus diagnosis of probable LBD was not more specific to LBD than the more lenient diagnosis of possible LBD. However, patients who accurately met criteria for probable LBD tended to have the most severe form of this neurodegenerative disease. A nonsignificant trend in the data suggested that accurate clinical diagnosis of LBD may be facilitated when concomitant AD pathology is less severe. In this sample, only 10% (4/39) of patients had any documentation of fluctuating cognition. Hence, the McKeith et al. 4 criteria were not useful in predicting LBD since they necessitate evidence of fluctuations. Other investigators have also reported difficulty in identifying this clinical feature. 5,6 Mega et al. 6 have suggested using a change of 5 or more points on the Mini- Mental State Examination 11 over three administrations within a 6-month period as evidence of fluctuating cognition; however, this objective criterion has yet to be validated. Exploratory analyses revealed a highly significant association between depression and LBD. In this sample population, the likelihood of having LBD as opposed to AD was 16 times greater if depression was evident. Although preliminary, this finding is noteworthy since depression is not a symptom that is considered as a criterion for LBD in any proposed set of clinical criteria for this disease. Klatka et al. 7 also reported significantly higher depression rates in LBD patients than in AD patients, with frequencies similar to those reported here (50% for LBD vs. 13.8% for AD patients). Also included in that study was a PD control group, in which depression was as common as in LBD. The high likelihood of depression in LBD may reflect a manifestation of LB pathology also common to PD. Although depression has also been reported in AD in varying rates, it is not necessarily considered a constant correlate of the disease. In PD, depression is the most commonly reported mental change. 12 Future investigations of the predictive validity of depression in diagnosing LBD are warranted and should employ standardized measures of depression. The exploratory analysis also revealed that falls and delusions were more common in AD than LBD patients in this sample. These results were surprising to us, being the opposite of what we had expected. We do not have any solid explanations for these findings. It is possible that our sample was unrepresentative in this regard. Alternatively, it may be that falls and delusions are not good distinguishers of LBD. There were several limitations to this study, including the use of chart review, retrospective assessment, and operator dependency in clinical documentation and interpretation of information contained within medical charts. In addition, some patients evaluations were more longitudinal than others, so that some documentations/observations were restricted to specific points in time rather than extended across the later lifespan. This confound is not easily addressed and places universal limitations on investigations of this disease, since most are retrospective in nature. Standardized, prospective, longitudinal documentation by geriatric specialists, including those with expertise in identifying mental, psychiatric, and movement disorders, is critical to further our knowledge of the clinical correlates of this disease. Furthermore, training specialists to identify cognitive fluctuations by some universally established criteria would likely improve the accuracy of LBD diagnosis and the utility of consensus criteria. An additional limitation to the interpretation of the present results is the forced correlation of longitudinal clinical data with static, end-state neuropathologic data. With these restrictions, it is not possible to ascertain whether AD or LB comes first in the neurodegenerative process and what, if any, relationship exists between the progression of these different pathologies. It is also not clear how each type of neuropathologic change (LBs, neurofibrillary plaques, tangles) relates to behavioral symptomatology, or whether clinical manifestations depend exclusively on the location of neural degeneration. Different groups of investigators have addressed this issue, without consensus. 3 Furthermore, since the neuropathologic diagnosis of LBD has not yet been standardized or validated, clinicopathologic correlations across samples are still difficult to compare. The number of publications addressing the nosologic entity of LBD has greatly increased over the past few years. Nonetheless, the contention that patients with LBD can be identified clinically with a reliable degree of accuracy is not fully supported by the data. Most of what has been described of this disease has been based on retrospective assessment. To be sure that LBD is a clinically diagnosable disease, prospective, longitudinal JOURNAL OF NEUROPSYCHIATRY 411

8 DIAGNOSIS OF LEWY BODY DISEASE studies using proposed clinical criteria would have to be conducted, with subsequent autopsy validation. Results would then have to be cross-validated in other, independent samples. This proposition would also require standardized and validated neuropathologic criteria for making a diagnosis of LBD. Only through such rigor could it truly be ascertained that LBD comprises a distinct, identifiable, age-related neurodegenerative disease process. A further understanding of the clinical profile, pathogenesis, and neuropathology associated with this disease would certainly facilitate our ability to successfully identify and potentially treat this patient population. This project was supported in part by a grant from the National Institute on Aging, Alzheimer s Disease Center (AG08665), and a Neurobiology of Aging Training Grant (AG00107). This work was presented at a poster session at the 9th annual meeting of the American Neuropsychiatric Association, Honolulu, HI, February 1 3, References 1. Perry R, Irving D, Blessed G, et al: Clinically and pathologically distinct form of dementia in the elderly (letter). Lancet 1989; 1: McKeith IG, Galasko D, Kosaka K, et al: Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB). Neurology 1996; 47: Papka M, Rubio A, Schiffer RB: A review of Lewy body disease, an emerging concept of cortical dementia. J Neuropsychiatry Clin Neurosci 1998; 10: McKeith I, Perry R, Fairbairn A, et al: Operational criteria for senile dementia of Lewy body type (SDLT). Psychol Med 1992; 22: McKeith I, Fairbairn A, Bothwell R, et al: An evaluation of the predictive validity and inter-rater reliability of clinical diagnostic criteria for senile dementia of Lewy body type. Neurology 1994; 44: Mega MS, Masterman DL, Benson DF, et al: Dementia with Lewy bodies: reliability and validity of clinical and pathologic criteria. Neurology 1996; 47: Klatka LA, Louis ED, Schiffer RB: Psychiatric features in diffuse Lewy body disease. Neurology 1996; 47: Braak H, Braak E: Neuropathological staging of Alzheimerrelated changes. Acta Neuropathol 1991;82: The National Institute on Aging and Ronald and Nancy Reagan Institute of Alzheimer s Association Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer s Disease: Consensus recommendations for the postmortem diagnosis of Alzheimer s disease. Neurobiol Aging 1977; 18(4 suppl):s1 S2 10. Uchihara T, Kondo H, Ikeda K, et al: Alzheimer-type pathology in melanin-bleached sections of substantia nigra. J Neurol 1995; 242: Folstein M, Folstein S, McHugh P: Mini-Mental State : a practical method for grading the cognitive state of patients for the physician. J Psychiatr Res 1975; 12: Mayeux R: Depression in the patient with Parkinson s disease. J Clin Psychiatry 1990; 51(7 suppl): VOLUME 10 NUMBER 4 FALL 1998

ORIGINAL CONTRIBUTION. Diagnostic Accuracy of Dementia With Lewy Bodies. to be the second

ORIGINAL CONTRIBUTION. Diagnostic Accuracy of Dementia With Lewy Bodies. to be the second ORIGINAL CONTRIBUTION Diagnostic Accuracy of Dementia With Lewy Bodies Ursula Hohl, MD; Pietro Tiraboschi, MD; Lawrence A. Hansen, MD; Leon J. Thal, MD; Jody Corey-Bloom, MD, PhD Background: Diagnostic

More information

Hallucinations and signs of parkinsonism help distinguish patients with dementia and cortical

Hallucinations and signs of parkinsonism help distinguish patients with dementia and cortical 161Journal of Neurology, Neurosurgery, and Psychiatry 1997;62:16-21 Alzheimer's Treatment and Research Center, Department of Neurology, Ramsey Clinic/Health- Partners, University of Minnesota, St Paul,

More information

ORIGINAL CONTRIBUTION. An Investigation of Clinical Correlates of Lewy Bodies in Autopsy-Proven Alzheimer Disease

ORIGINAL CONTRIBUTION. An Investigation of Clinical Correlates of Lewy Bodies in Autopsy-Proven Alzheimer Disease ORIGINAL CONTRIBUTION An Investigation of Clinical Correlates of Lewy Bodies in Autopsy-Proven Alzheimer Disease Yaakov Stern, PhD; Diane Jacobs, PhD; James Goldman, MD; Estrella Gomez-Tortosa, PhD; Bradley

More information

Non Alzheimer Dementias

Non Alzheimer Dementias Non Alzheimer Dementias Randolph B Schiffer Department of Neuropsychiatry and Behavioral Science Texas Tech University Health Sciences Center 9/11/2007 Statement of Financial Disclosure Randolph B Schiffer,,

More information

A prospective study of dementia with Lewy bodies

A prospective study of dementia with Lewy bodies Age and Ageing 998; 27: 6-66 998, British Geriatrics Society A prospective study of dementia with Lewy bodies CLIVE G. BALLARD, JOHN O'BRIEN, KATH LOWERX GARETH A. AYRE, RICHARD HARRISON, ROBERT PERRY,

More information

Clinical Diagnosis. Step 1: Dementia or not? Diagnostic criteria for dementia (DSM-IV)

Clinical Diagnosis. Step 1: Dementia or not? Diagnostic criteria for dementia (DSM-IV) Step 1: Dementia or not? Diagnostic criteria for dementia (DSM-IV) A. The development of multiple cognitive deficits manifested by both 1 and 2 1 1. Memory impairment 2. One (or more) of the following

More information

Neuropathology of Neurodegenerative Disorders Prof. Jillian Kril

Neuropathology of Neurodegenerative Disorders Prof. Jillian Kril Neurodegenerative disorders to be discussed Alzheimer s disease Lewy body diseases Frontotemporal dementia and other tauopathies Huntington s disease Motor Neuron Disease 2 Neuropathology of neurodegeneration

More information

Pentagon copying is more impaired in dementia with Lewy bodies than in Alzheimer s disease

Pentagon copying is more impaired in dementia with Lewy bodies than in Alzheimer s disease J Neurol Neurosurg Psychiatry 2001;70:483 488 483 Center for Alzheimer Disease and Related Disorders, Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois, USA

More information

Dementia. Stephen S. Flitman, MD Medical Director 21st Century Neurology

Dementia. Stephen S. Flitman, MD Medical Director 21st Century Neurology Dementia Stephen S. Flitman, MD Medical Director 21st Century Neurology www.neurozone.org Dementia is a syndrome Progressive memory loss, plus Progressive loss of one or more cognitive functions: Language

More information

Dementia and Healthy Ageing : is the pathology any different?

Dementia and Healthy Ageing : is the pathology any different? Dementia and Healthy Ageing : is the pathology any different? Professor David Mann, Professor of Neuropathology, University of Manchester, Hope Hospital, Salford DEMENTIA Loss of connectivity within association

More information

Dementia Update. October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada

Dementia Update. October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada Dementia Update October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada Outline New concepts in Alzheimer disease Biomarkers and in vivo diagnosis Future trends

More information

Predicting Lewy Body Pathology in a Community-Based Sample With Clinical Diagnosis of Alzheimer s Disease

Predicting Lewy Body Pathology in a Community-Based Sample With Clinical Diagnosis of Alzheimer s Disease Predicting Lewy Body Pathology in a Community-Based Sample With Clinical Diagnosis of Alzheimer s Disease Debby Tsuang, MD, MSc, Kate Simpson, MPH, Eric B. Larson, MD, MPH, Elaine Peskind, MD, Walter Kukull,

More information

Improving diagnosis of Alzheimer s disease and lewy body dementia. Brain TLC October 2018

Improving diagnosis of Alzheimer s disease and lewy body dementia. Brain TLC October 2018 Improving diagnosis of Alzheimer s disease and lewy body dementia Brain TLC October 2018 Plan for this discussion: Introduction to AD and LBD Why do we need to improve diagnosis? What progress has been

More information

The Spectrum of Age-Associated Astroglial Tauopathies. Dennis W. Dickson MD Department of Neuroscience Mayo Clinic, Jacksonville, FL

The Spectrum of Age-Associated Astroglial Tauopathies. Dennis W. Dickson MD Department of Neuroscience Mayo Clinic, Jacksonville, FL The Spectrum of Age-Associated Astroglial Tauopathies Dennis W. Dickson MD Mayo Clinic, Jacksonville, FL Thorn-shaped astrocytes TSA were first reported by Ikeda (1995), as tau-positive astrocytes in various

More information

The ABCs of Dementia Diagnosis

The ABCs of Dementia Diagnosis The ABCs of Dementia Diagnosis Dr. Robin Heinrichs, Ph.D., ABPP Board Certified Clinical Neuropsychologist Associate Professor, Psychiatry & Behavioral Sciences Director of Neuropsychology Training What

More information

What if it s not Alzheimer s? Update on Lewy body dementia and frontotemporal dementia

What if it s not Alzheimer s? Update on Lewy body dementia and frontotemporal dementia What if it s not Alzheimer s? Update on Lewy body dementia and frontotemporal dementia Dementia: broad term for any acquired brain condition impairing mental function such that ADLs are impaired. Includes:

More information

Revised criteria for the clinical diagnosis of dementia with Lewy. Dementia with Lewy bodies. (Dementia with Lewy Bodies)

Revised criteria for the clinical diagnosis of dementia with Lewy. Dementia with Lewy bodies. (Dementia with Lewy Bodies) Dementia with Lewy bodies First described: Okazaki H, 1961, Diffuse intracytoplasmic ganglionic inclusions (Lewy type) associated with progressive dementia and quadriparesis in flexion. J Neuropathol Exp

More information

Caring Sheet #11: Alzheimer s Disease:

Caring Sheet #11: Alzheimer s Disease: CARING SHEETS: Caring Sheet #11: Alzheimer s Disease: A Summary of Information and Intervention Suggestions with an Emphasis on Cognition By Shelly E. Weaverdyck, PhD Introduction This caring sheet focuses

More information

MOVEMENT DISORDERS AND DEMENTIA

MOVEMENT DISORDERS AND DEMENTIA MOVEMENT DISORDERS AND DEMENTIA FOCUS ON DEMENTIA WITH LEWY BODIES MADHAVI THOMAS MD NORTH TEXAS MOVEMENT DISORDERS INSTITUTE, INC DEMENTIA de men tia dəˈmen(t)sh(ē)ə/ nounmedicine noun: dementia a chronic

More information

Introduction, use of imaging and current guidelines. John O Brien Professor of Old Age Psychiatry University of Cambridge

Introduction, use of imaging and current guidelines. John O Brien Professor of Old Age Psychiatry University of Cambridge Introduction, use of imaging and current guidelines John O Brien Professor of Old Age Psychiatry University of Cambridge Why do we undertake brain imaging in AD and other dementias? Exclude other causes

More information

NACC Neuropathology (NP) Diagnosis Coding Guidebook

NACC Neuropathology (NP) Diagnosis Coding Guidebook Department of Epidemiology, School of Public Health and Community Medicine, University of Washington 4311 11 th Avenue NE #300 Seattle, WA 98105 phone: (206) 543-8637; fax: (206) 616-5927 e-mail: naccmail@u.washington.edu

More information

Frontotemporal dementia and dementia with Lewy bodies in a case-control study of Alzheimer s disease

Frontotemporal dementia and dementia with Lewy bodies in a case-control study of Alzheimer s disease International Psychogeriatrics: page 1 of 8 C 2009 International Psychogeriatric Association doi:10.1017/s1041610209009454 Frontotemporal dementia and dementia with Lewy bodies in a case-control study

More information

NACC Vascular Consortium. NACC Vascular Consortium. NACC Vascular Consortium

NACC Vascular Consortium. NACC Vascular Consortium. NACC Vascular Consortium NACC Vascular Consortium NACC Vascular Consortium Participating centers: Oregon Health and Science University ADC Rush University ADC Mount Sinai School of Medicine ADC Boston University ADC In consultation

More information

Delirium & Dementia. Nicholas J. Silvestri, MD

Delirium & Dementia. Nicholas J. Silvestri, MD Delirium & Dementia Nicholas J. Silvestri, MD Outline Delirium vs. Dementia Neural pathways relating to consciousness Encephalopathy Stupor Coma Dementia Delirium vs. Dementia Delirium Abrupt onset Lasts

More information

Clinicopathologic and genetic aspects of hippocampal sclerosis. Dennis W. Dickson, MD Mayo Clinic, Jacksonville, Florida USA

Clinicopathologic and genetic aspects of hippocampal sclerosis. Dennis W. Dickson, MD Mayo Clinic, Jacksonville, Florida USA Clinicopathologic and genetic aspects of hippocampal sclerosis Dennis W. Dickson, MD Mayo Clinic, Jacksonville, Florida USA The hippocampus in health & disease A major structure of the medial temporal

More information

ORIGINAL CONTRIBUTION. Diagnostic Validity of the Dementia Questionnaire for Alzheimer Disease

ORIGINAL CONTRIBUTION. Diagnostic Validity of the Dementia Questionnaire for Alzheimer Disease ORIGINAL CONTRIBUTION Diagnostic Validity of the Dementia Questionnaire for Alzheimer Disease Ronald J. Ellis, MD, PhD; Kaining Jan, MD; Claudia Kawas, MD; William C. Koller, MD; Kelly E. Lyons, PhD; Dilip

More information

7/3/2013 ABNORMAL PSYCHOLOGY SEVENTH EDITION CHAPTER FOURTEEN CHAPTER OUTLINE. Dementia, Delirium, and Amnestic Disorders. Oltmanns and Emery

7/3/2013 ABNORMAL PSYCHOLOGY SEVENTH EDITION CHAPTER FOURTEEN CHAPTER OUTLINE. Dementia, Delirium, and Amnestic Disorders. Oltmanns and Emery ABNORMAL PSYCHOLOGY SEVENTH EDITION Oltmanns and Emery PowerPoint Presentations Prepared by: Ashlea R. Smith, Ph.D. This multimedia and its contents are protected under copyright law. The following are

More information

Form D1: Clinician Diagnosis

Form D1: Clinician Diagnosis Initial Visit Packet Form D: Clinician Diagnosis NACC Uniform Data Set (UDS) ADC name: Subject ID: Form date: / / Visit #: Examiner s initials: INSTRUCTIONS: This form is to be completed by the clinician.

More information

FDG-PET e parkinsonismi

FDG-PET e parkinsonismi Parkinsonismi FDG-PET e parkinsonismi Valentina Berti Dipartimento di Scienze Biomediche, Sperimentali e Cliniche Sez. Medicina Nucleare Università degli Studi di Firenze History 140 PubMed: FDG AND parkinsonism

More information

How to Diagnose Early (Prodromal) Lewy Body Dementia. Ian McKeith MD, FRCPsych, F Med Sci.

How to Diagnose Early (Prodromal) Lewy Body Dementia. Ian McKeith MD, FRCPsych, F Med Sci. How to Diagnose Early (Prodromal) Lewy Body Dementia Ian McKeith MD, FRCPsych, F Med Sci. Parkinson s Disease Lewy Body Disease Time PD Dementia Lewy Body Dementias Dementia with Lewy Bodies (DLB) Diagnostic

More information

Visual Hallucinations in Dementia: A Prospective Community-Based Study With Autopsy

Visual Hallucinations in Dementia: A Prospective Community-Based Study With Autopsy Visual Hallucinations in Dementia: A Prospective Community-Based Study With Autopsy Debby Tsuang, M.D., M.Sc., Eric B. Larson, M.D., M.P.H., Elizabeth Bolen, B.S., Mary Lou Thompson, Ph.D., Elaine Peskind,

More information

Predictors of disease course in patients with probable Alzheimer's disease

Predictors of disease course in patients with probable Alzheimer's disease Article abstract-the presence of extrapyramidal signs or psychosis may indicate greater disability in patients with probable Alzheimer's disease. We evaluated the ability of these signs, noted at a patient's

More information

ORIGINAL CONTRIBUTION. Apolipoprotein E 4 Is a Determinant for Alzheimer-Type Pathologic Features in Tauopathies, Synucleinopathies,

ORIGINAL CONTRIBUTION. Apolipoprotein E 4 Is a Determinant for Alzheimer-Type Pathologic Features in Tauopathies, Synucleinopathies, ORIGINAL CONTRIBUTION Apolipoprotein E 4 Is a Determinant for Alzheimer-Type Pathologic Features in Tauopathies, Synucleinopathies, and Frontotemporal Degeneration Keith A. Josephs, MST, MD; Yoshio Tsuboi,

More information

WHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient

WHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient DEMENTIA WHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient Progressive and disabling Not an inherent aspect of

More information

Baseline Characteristics of Patients Attending the Memory Clinic Serving the South Shore of Boston

Baseline Characteristics of Patients Attending the   Memory Clinic Serving the South Shore of Boston Article ID: ISSN 2046-1690 Baseline Characteristics of Patients Attending the www.thealzcenter.org Memory Clinic Serving the South Shore of Boston Corresponding Author: Dr. Anil K Nair, Chief of Neurology,

More information

Dementia. Dr Maria Foundas Consultant Physician. Training support Skills development Competency Assessment Scholarships Education

Dementia. Dr Maria Foundas Consultant Physician. Training support Skills development Competency Assessment Scholarships Education Dementia Dr Maria Foundas Consultant Physician Training support Skills development Competency Assessment Scholarships Education Preamble and disclaimer These slides are made available by the Western Australian

More information

United Council for Neurologic Subspecialties Geriatric Neurology Written Examination Content Outline

United Council for Neurologic Subspecialties Geriatric Neurology Written Examination Content Outline United Council for Neurologic Subspecialties Geriatric Neurology Written Examination Content Outline REV 3/24/09 The UCNS Geriatric Neurology examination was established to determine the level of competence

More information

Resistance to forgetting associated with hippocampus-mediated. reactivation during new learning

Resistance to forgetting associated with hippocampus-mediated. reactivation during new learning Resistance to Forgetting 1 Resistance to forgetting associated with hippocampus-mediated reactivation during new learning Brice A. Kuhl, Arpeet T. Shah, Sarah DuBrow, & Anthony D. Wagner Resistance to

More information

C linicians have noted a close association between. Lewy body cortical involvement may not always predict dementia in Parkinson s disease PAPER

C linicians have noted a close association between. Lewy body cortical involvement may not always predict dementia in Parkinson s disease PAPER 852 PAPER Lewy body cortical involvement may not always predict dementia in Parkinson s disease C Colosimo, A J Hughes, L Kilford, A J Lees... See end of article for authors affiliations... Correspondence

More information

DEMENTIA 101: WHAT IS HAPPENING IN THE BRAIN? Philip L. Rambo, PhD

DEMENTIA 101: WHAT IS HAPPENING IN THE BRAIN? Philip L. Rambo, PhD DEMENTIA 101: WHAT IS HAPPENING IN THE BRAIN? Philip L. Rambo, PhD OBJECTIVES Terminology/Dementia Basics Most Common Types Defining features Neuro-anatomical/pathological underpinnings Neuro-cognitive

More information

Pathogenesis of Degenerative Diseases and Dementias. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria)

Pathogenesis of Degenerative Diseases and Dementias. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria) Pathogenesis of Degenerative Diseases and Dementias D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria) Dementias Defined: as the development of memory impairment and other cognitive deficits

More information

ORIGINAL CONTRIBUTION. Accuracy of the Clinical Diagnoses of Lewy Body Disease, Parkinson Disease, and Dementia With Lewy Bodies

ORIGINAL CONTRIBUTION. Accuracy of the Clinical Diagnoses of Lewy Body Disease, Parkinson Disease, and Dementia With Lewy Bodies Accuracy of the Clinical Diagnoses of Lewy Body Disease, Parkinson Disease, and Dementia With Lewy Bodies A Clinicopathologic Study ORIGINAL CONTRIBUTION I. Litvan, MD; A. MacIntyre, MHS; C. G. Goetz,

More information

The Person: Dementia Basics

The Person: Dementia Basics The Person: Dementia Basics Objectives 1. Discuss how expected age related changes in the brain might affect an individual's cognition and functioning 2. Discuss how changes in the brain due to Alzheimer

More information

Simulated brain biopsy for diagnosing neurodegeneration using autopsy-confirmed cases

Simulated brain biopsy for diagnosing neurodegeneration using autopsy-confirmed cases Acta Neuropathol (2011) 122:737 745 DOI 10.1007/s00401-011-0880-5 ORIGINAL PAPER Simulated brain biopsy for diagnosing neurodegeneration using autopsy-confirmed cases Sriram Venneti John L. Robinson Subhojit

More information

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. Introduction. Parkinson's disease (PD) has been considered largely as a motor disorder. It has been increasingly recognized that

More information

OLD AGE PSYCHIATRY. Dementia definition TYPES OF DEMENTIA. Other causes. Psychiatric disorders of the elderly. Dementia.

OLD AGE PSYCHIATRY. Dementia definition TYPES OF DEMENTIA. Other causes. Psychiatric disorders of the elderly. Dementia. Psychiatric disorders of the elderly OLD AGE PSYCHIATRY Dementia Depression Delusional disorder/late onset schizophrenia Delirium Dementia definition LOCALISATION OF CEREBRAL FUNCTION Impairment of multiple

More information

Dementia and Delirium

Dementia and Delirium Dementia and Delirium LPT Gondar Mental Health Group www.le.ac.uk Dementia and Delirium WTINP Chapter 4.6 Introduction - areas to be covered Delirium Definition and causes Clinical features Management

More information

Parkinsonian Disorders with Dementia

Parkinsonian Disorders with Dementia Parkinsonian Disorders with Dementia George Tadros Consultant in Old Age Liaison Psychiatry, RAID, Heartlands Hospital Professor of Dementia and Liaison Psychiatry, Aston Medical School Aston University

More information

Dementia Update. Daniel Drubach, M.D. Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota

Dementia Update. Daniel Drubach, M.D. Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota Dementia Update Daniel Drubach, M.D. Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota Nothing to disclose Dementia Progressive deterioration in mental function

More information

Dementia with Lewy Bodies. A Distinct Non-Alzheimer Dementia Syndrome?

Dementia with Lewy Bodies. A Distinct Non-Alzheimer Dementia Syndrome? Brain Pathology 8: 299-324(1998) Dementia with Lewy Bodies. A Distinct Non-Alzheimer Dementia Syndrome? Paul G. Ince 1, 2, Elaine K. Perry 1, Chris. M. Morris 1 MRC Neurochemical Pathology Unit 1, University

More information

Objectives. RAIN Difficult Diagnosis 2014: A 75 year old woman with falls. Case History: First visit. Case History: First Visit

Objectives. RAIN Difficult Diagnosis 2014: A 75 year old woman with falls. Case History: First visit. Case History: First Visit Objectives RAIN Difficult Diagnosis 2014: A 75 year old woman with falls Alexandra Nelson MD, PhD UCSF Memory and Aging Center/Gladstone Institute of Neurological Disease Recognize important clinical features

More information

ALZHEIMER S DISEASE. Mary-Letitia Timiras M.D. Overlook Hospital Summit, New Jersey

ALZHEIMER S DISEASE. Mary-Letitia Timiras M.D. Overlook Hospital Summit, New Jersey ALZHEIMER S DISEASE Mary-Letitia Timiras M.D. Overlook Hospital Summit, New Jersey Topics Covered Demography Clinical manifestations Pathophysiology Diagnosis Treatment Future trends Prevalence and Impact

More information

Dementia: How to explain the diagnosis to patients and relatives

Dementia: How to explain the diagnosis to patients and relatives GPHot Topics (April 2017): Dementia: How to explain the diagnosis to patients and relatives mohammad somauroo Consultant Physician with specialist interest in Community Geriatrics Royal Liverpool and Broadgreen

More information

! slow, progressive, permanent loss of neurologic function.

! slow, progressive, permanent loss of neurologic function. UBC ! slow, progressive, permanent loss of neurologic function.! cause unknown.! sporadic, familial or inherited.! degeneration of specific brain region! clinical syndrome.! pathology: abnormal accumulation

More information

A Fresh View of Cognitive Disorders in Older Adults: New Classification and Screening Strategies

A Fresh View of Cognitive Disorders in Older Adults: New Classification and Screening Strategies A Fresh View of Cognitive Disorders in Older Adults: New Classification and Screening Strategies Lynda Mackin, PhD, AGPCNP-BC, CNS University of California San Francisco School of Nursing 1 Alzheimer s

More information

Neuro degenerative PET image from FDG, amyloid to Tau

Neuro degenerative PET image from FDG, amyloid to Tau Neuro degenerative PET image from FDG, amyloid to Tau Kun Ju Lin ( ) MD, Ph.D Department of Nuclear Medicine and Molecular Imaging Center, Chang Gung Memorial Hospital ( ) Department of Medical Imaging

More information

ORIGINAL CONTRIBUTION. Regional Distribution of Neuritic Plaques in the Nondemented Elderly and Subjects With Very Mild Alzheimer Disease

ORIGINAL CONTRIBUTION. Regional Distribution of Neuritic Plaques in the Nondemented Elderly and Subjects With Very Mild Alzheimer Disease ORIGINAL CONTRIBUTION Regional Distribution of Neuritic Plaques in the Nondemented Elderly and Subjects With Very Mild Alzheimer Disease Vahram Haroutunian, PhD; Daniel P. Perl, MD; Dushyant P. Purohit,

More information

Update on functional brain imaging in Movement Disorders

Update on functional brain imaging in Movement Disorders Update on functional brain imaging in Movement Disorders Mario Masellis, MSc, MD, FRCPC, PhD Assistant Professor & Clinician-Scientist Sunnybrook Health Sciences Centre University of Toronto 53 rd CNSF

More information

Lecture 42: Final Review. Martin Wessendorf, Ph.D.

Lecture 42: Final Review. Martin Wessendorf, Ph.D. Lecture 42: Final Review Martin Wessendorf, Ph.D. Lecture 33 cortex Heilbronner 5 lobes of the cortex Lateral view (left side) Mid-saggital view (right side) Cellular organization of cortex White matter

More information

UDS version 3 Summary of major changes to UDS form packets

UDS version 3 Summary of major changes to UDS form packets UDS version 3 Summary of major changes to UDS form packets from version 2 to VERSION 3 february 18 final Form A1: Subject demographics Updated question on principal referral source to add additional options

More information

Parkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee

Parkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee Parkinson Disease Lorraine Kalia, MD, PhD, FRCPC Key Learnings Parkinson Disease (L. Kalia) Key Learnings Parkinson disease is the most common but not the only cause of parkinsonism Parkinson disease is

More information

Clinical features of dementia with lewy bodies in 35 Chinese patients

Clinical features of dementia with lewy bodies in 35 Chinese patients Han et al. Translational Neurodegeneration 2014, 3:1 Translational Neurodegeneration RESEARCH Open Access Clinical features of dementia with lewy bodies in 35 Chinese patients Ding Han, Qiong Wang, Zhongbao

More information

Epilepsy in dementia. Case 1. Dr. Yotin Chinvarun M..D. Ph.D. 5/25/16. CEP, PMK hospital

Epilepsy in dementia. Case 1. Dr. Yotin Chinvarun M..D. Ph.D. 5/25/16. CEP, PMK hospital Epilepsy in dementia Dr. Yotin Chinvarun M..D. Ph.D. CEP, PMK hospital Case 1 M 90 years old Had a history of tonic of both limbs (Lt > Rt) at the age of 88 years old, eye rolled up, no grunting, lasting

More information

Palliative Approach to the Person with Advanced Dementia

Palliative Approach to the Person with Advanced Dementia Mid North Coast Rural Palliative Care Project Link Nurse Education 2004 Palliative Approach to the Person with Advanced Dementia Anne Sneesby CNC - ACAT To care for the dying is a very human opportunity

More information

III./3.1. Movement disorders with akinetic rigid symptoms

III./3.1. Movement disorders with akinetic rigid symptoms III./3.1. Movement disorders with akinetic rigid symptoms III./3.1.1. Parkinson s disease Parkinson s disease (PD) is the second most common neurodegenerative disorder worldwide after Alzheimer s disease.

More information

Role of TDP-43 in Non-Alzheimer s and Alzheimer s Neurodegenerative Diseases

Role of TDP-43 in Non-Alzheimer s and Alzheimer s Neurodegenerative Diseases Role of TDP-43 in Non-Alzheimer s and Alzheimer s Neurodegenerative Diseases Keith A. Josephs, MD, MST, MSc Professor of Neurology 13th Annual Mild Cognitive Impairment (MCI) Symposium: Alzheimer and Non-Alzheimer

More information

T he prevalence of Parkinson s disease (PD) is nearly 1% in

T he prevalence of Parkinson s disease (PD) is nearly 1% in 708 PAPER Donepezil for cognitive impairment in Parkinson s disease: a randomised controlled study D Aarsland, K Laake, J P Larsen, C Janvin... See end of article for authors affiliations... Correspondence

More information

What is Neuropsychology?

What is Neuropsychology? Alzheimer s Disease Neurological Bases and Informed Behavioral Interventions Peter T. Keenan Clinical Neuropsychologist Marshfield Clinic Minocqua Center What is Neuropsychology? Science of the relationship

More information

Clinical Research on Treating Senile Dementia by Combining Acupuncture with Acupoint-Injection

Clinical Research on Treating Senile Dementia by Combining Acupuncture with Acupoint-Injection Clinical Research on Treating Senile Dementia by Combining Acupuncture with Acupoint-Injection Yemeng Chen, M.D. Acupuncture Department, Huashan Hospital Shanghai Medical University, Shanghai 20040, P.

More information

Adverse Outcomes After Hospitalization and Delirium in Persons With Alzheimer Disease

Adverse Outcomes After Hospitalization and Delirium in Persons With Alzheimer Disease Adverse Outcomes After Hospitalization and Delirium in Persons With Alzheimer Disease J. Sukanya 05.Jul.2012 Outline Background Methods Results Discussion Appraisal Background Common outcomes in hospitalized

More information

Diagnosis before NIA AA The impact of FDG PET in. Diagnosis after NIA AA Neuropathology and PET image 2015/10/16

Diagnosis before NIA AA The impact of FDG PET in. Diagnosis after NIA AA Neuropathology and PET image 2015/10/16 The impact of FDG PET in degenerative dementia diagnosis Jung Lung, Hsu MD, Ph.D (Utrecht) Section of dementia and cognitive impairment Department of Neurology Chang Gung Memorial Hospital, Linkou, Taipei

More information

P20.2. Characteristics of different types of dementia and challenges for the clinician

P20.2. Characteristics of different types of dementia and challenges for the clinician P20.2. Characteristics of different types of dementia and challenges for the clinician, professor Danish Dementia Research Center Rigshospitalet, University of Copenhagen (Denmark) This project has received

More information

CHAPTER 5 NEUROPSYCHOLOGICAL PROFILE OF ALZHEIMER S DISEASE

CHAPTER 5 NEUROPSYCHOLOGICAL PROFILE OF ALZHEIMER S DISEASE CHAPTER 5 NEUROPSYCHOLOGICAL PROFILE OF ALZHEIMER S DISEASE 5.1 GENERAL BACKGROUND Neuropsychological assessment plays a crucial role in the assessment of cognitive decline in older age. In India, there

More information

Neuropsychiatric Symptoms of Patients With Progressive Supranuclear Palsy and Parkinson s Disease

Neuropsychiatric Symptoms of Patients With Progressive Supranuclear Palsy and Parkinson s Disease Neuropsychiatric Symptoms of Patients With Progressive Supranuclear Palsy and Parkinson s Disease Dag Aarsland, M.D., Ph.D. Irene Litvan, M.D. Jan P. Larsen, M.D., Ph.D. Neuropsychiatric symptoms are common

More information

Lewy Body-Related -Synucleinopathy in Aging

Lewy Body-Related -Synucleinopathy in Aging Journal of Neuropathology and Experimental Neurology Vol. 6, No. 7 Copyright 4 by the American Association of Neuropathologists July, 4 pp. 74 749 Lewy Body-Related -Synucleinopathy in Aging YUKO SAITO,

More information

ORIGINAL CONTRIBUTION. Cerebrospinal Fluid -Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic

ORIGINAL CONTRIBUTION. Cerebrospinal Fluid -Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic ORIGINAL CONTRIBUTION Cerebrospinal Fluid -Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain Tero Tapiola, MD, PhD; Irina Alafuzoff, MD, PhD; Sanna-Kaisa Herukka,

More information

Chronic Traumatic Encephalopathy Provider and Parent Essentials

Chronic Traumatic Encephalopathy Provider and Parent Essentials Chronic Traumatic Encephalopathy Provider and Parent Essentials Concussion Global Cast July 30, 2014 John Lockhart, MD Seattle Children s Hospital Chronic Traumatic Encephaly (CTE) Working Definition Chronic

More information

DIFFERENTIAL DIAGNOSIS SARAH MARRINAN

DIFFERENTIAL DIAGNOSIS SARAH MARRINAN Parkinson s Academy Registrar Masterclass Sheffield DIFFERENTIAL DIAGNOSIS SARAH MARRINAN 17 th September 2014 Objectives Importance of age in diagnosis Diagnostic challenges Brain Bank criteria Differential

More information

Yin-Hui Siow MD, FRCPC Director of Nuclear Medicine Southlake Regional Health Centre

Yin-Hui Siow MD, FRCPC Director of Nuclear Medicine Southlake Regional Health Centre Yin-Hui Siow MD, FRCPC Director of Nuclear Medicine Southlake Regional Health Centre Today Introduction to CT Introduction to MRI Introduction to nuclear medicine Imaging the dementias The Brain ~ 1.5

More information

Overview of neurological changes in Alzheimer s disease. Eric Karran

Overview of neurological changes in Alzheimer s disease. Eric Karran Overview of neurological changes in Alzheimer s disease Eric Karran Alzheimer s disease Alois Alzheimer 1864-1915 Auguste D. 1850-1906 Case presented November 26 th 1906 Guildford Talk.ppt 20 th March,

More information

Dementia. Assessing Brain Damage. Mental Status Examination

Dementia. Assessing Brain Damage. Mental Status Examination Dementia Assessing Brain Damage Mental status examination Information about current behavior and thought including orientation to reality, memory, and ability to follow instructions Neuropsychological

More information

The Spectrum of Lewy Body Disease: Dementia with Lewy Bodies and Parkinson's Disease Dementia

The Spectrum of Lewy Body Disease: Dementia with Lewy Bodies and Parkinson's Disease Dementia Disclosures Research support, Parkinson Society Canada, Canadian Institutes of Health Research, Ministry of Economic Development and Innovation, Teva Novartis clinical trial, Principal Investigator CME

More information

Dementia. Aetiology, pathophysiology and the role of neuropsychological testing. Dr Sheng Ling Low Geriatrician

Dementia. Aetiology, pathophysiology and the role of neuropsychological testing. Dr Sheng Ling Low Geriatrician Dementia Aetiology, pathophysiology and the role of neuropsychological testing Dr Sheng Ling Low Geriatrician Topics to cover Why is dementia important What is dementia Differentiate between dementia,

More information

The Carroll A. Campbell, Jr. Neuropathology Laboratory: A Tool for Dementia Discovery in South Carolina

The Carroll A. Campbell, Jr. Neuropathology Laboratory: A Tool for Dementia Discovery in South Carolina The Carroll A. Campbell, Jr. Neuropathology Laboratory: A Tool for Dementia Discovery in South Carolina Pathology in the Cerebral Cortex H&E stain of mature neuritic plaque Modified Bielschowsky stain

More information

ASYMMETRICAL CORTICAL DEGENERATIVE SYNDROMES

ASYMMETRICAL CORTICAL DEGENERATIVE SYNDROMES ASYMMETRICAL CORTICAL DEGENERATIVE SYNDROMES Richard Caselli, MD Professor & Chair, Department of Neurology Mayo Clinic Arizona & Clinical Core Director, Arizona Alzheimer s Disease Center Objectives:

More information

Old Age and Stress. Disorders of Aging and Cognition. Disorders of Aging and Cognition. Chapter 18

Old Age and Stress. Disorders of Aging and Cognition. Disorders of Aging and Cognition. Chapter 18 Disorders of Aging and Cognition Chapter 18 Slides & Handouts by Karen Clay Rhines, Ph.D. Northampton Community College Comer, Abnormal Psychology, 8e Disorders of Aging and Cognition Dementia deterioration

More information

Common Forms of Dementia Handout Package

Common Forms of Dementia Handout Package Common Forms of Dementia Handout Package Common Forms of Dementia 1 Learning Objectives As a result of working through this module, you should be better able to: 1. Describe clinical features of 4 major

More information

WEBINAR SERIES: AGING IN INDIVIDUALS WITH INTELLECTUAL AND DEVELOPMENTAL DISABILITIES

WEBINAR SERIES: AGING IN INDIVIDUALS WITH INTELLECTUAL AND DEVELOPMENTAL DISABILITIES WEBINAR SERIES: AGING IN INDIVIDUALS WITH INTELLECTUAL AND DEVELOPMENTAL DISABILITIES 1 CMS Medicare-Medicaid Coordination Office (MMCO) Established by Section 2602 of the Affordable Care Act Purpose:

More information

Dementia Past, Present and Future

Dementia Past, Present and Future Dementia Past, Present and Future Morris Freedman MD, FRCPC Division of Neurology Baycrest and University of Toronto Rotman Research Institute, Baycrest CNSF 2015 Objectives By the end of this presentation,

More information

doi: /brain/awq141 Brain 2010: 133; Age, Alzheimer s disease and dementia in the Baltimore Longitudinal Study of Ageing

doi: /brain/awq141 Brain 2010: 133; Age, Alzheimer s disease and dementia in the Baltimore Longitudinal Study of Ageing doi:10.1093/brain/awq141 Brain 2010: 133; 2225 2231 2225 BRAIN A JOURNAL OF NEUROLOGY Age, Alzheimer s disease and dementia in the Baltimore Longitudinal Study of Ageing David Dolan, 1 Juan Troncoso, 2

More information

NEUROPATHOLOGY BRAIN CUTTING MANUAL LAST UPDATED ON 6/22/2015

NEUROPATHOLOGY BRAIN CUTTING MANUAL LAST UPDATED ON 6/22/2015 NEUROPATHOLOGY BRAIN CUTTING MANUAL LAST UPDATED ON 6/22/2015 Neuropathology Faculty involved in Brain Cutting: Dr. Sandra Camelo-Piragua Dr. Andrew Lieberman (Chief of the Division) Dr. Kathryn A. McFadden

More information

What About Dementia? Module 8, Part B (With Dr Allison Lamont)

What About Dementia? Module 8, Part B (With Dr Allison Lamont) What About Dementia? Module 8, Part B (With Dr Allison Lamont) Slide 1 Module 8 Part B will address the question What about dementia? Several surveys of older people both in the UK and USA have shown that

More information

Chapter 15: Late Life and Psychological Disorders

Chapter 15: Late Life and Psychological Disorders \ Chapter 15: Late Life and Psychological Disorders 1. Ageism refers to a. the physical deterioration that accompanies old age. b. the intellectual deterioration that frequently occurs as a person ages.

More information

PHYSIOLOGY of LIMBIC SYSTEM

PHYSIOLOGY of LIMBIC SYSTEM PHYSIOLOGY of LIMBIC SYSTEM By Dr. Mudassar Ali Roomi (MBBS, M.Phil.) Assistant Professor Physiology Limbic system: (shown in dark pink) Limbic = border Definition: limbic system means the entire neuronal

More information

Type 2 Diabetes and Brain Disease in Older Adults. Erin L. Abner, PhD, MPH Asst. Professor University Of Kentucky

Type 2 Diabetes and Brain Disease in Older Adults. Erin L. Abner, PhD, MPH Asst. Professor University Of Kentucky Type 2 Diabetes and Brain Disease in Older Adults Erin L. Abner, PhD, MPH Asst. Professor University Of Kentucky Disclosures to Participants Requirements for Successful Completion: For successful completion,

More information

What APS Workers Need to Know about Frontotemporal, Lewy Body and Vascular Dementias

What APS Workers Need to Know about Frontotemporal, Lewy Body and Vascular Dementias What APS Workers Need to Know about Frontotemporal, Lewy Body and Vascular Dementias Presenter: Kim Bailey, MS Gerontology, Program & Education Specialist, Alzheimer s Orange County 1 1 Facts About Our

More information

Clinical Differences Among Four Common Dementia Syndromes. a program of Morningside Ministries

Clinical Differences Among Four Common Dementia Syndromes. a program of Morningside Ministries Clinical Differences Among Four Common Dementia Syndromes a program of Morningside Ministries Introduction Four clinical dementia syndromes account for 90% of all cases after excluding reversible causes

More information

Dementia: Diagnosis and Treatment

Dementia: Diagnosis and Treatment Dementia: Diagnosis and Treatment Outline 1. Risk factors and definition of dementia 2. Types of Dementias 3. MMSE and testing 4. Treatment options Cognitive decline with aging Mild changes in memory and

More information

Synaptic changes in dementia: links to cognition and behaviour

Synaptic changes in dementia: links to cognition and behaviour Synaptic changes in dementia: links to cognition and behaviour Paul T Francis, PhD Professor of Neurochemistry Director, Brains for Dementia Research Agenda Discuss synaptic changes in various dementias

More information